Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of Filgrastim Hospira vs Neupogen in Healthy Volunteers
NCT02766634Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of filgrastim in neutropenia (2 arms), sponsored by Pfizer. Primary endpoints: Area under the effect curve for CD34+ at Day 10, Maximum observed value for CD34+ at Day 10 and 2 more. Started Mar 2016; status: completed.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02766634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766634.